Trump Treasury Proposes Wider Curbs on U.S. Investment in China Tech

The Trump administration has proposed a broader system for restricting or requiring notice of certain U.S. investments in sensitive technologies tied to China and other foreign adversaries. The Treasury Department announced the proposed rule on October 22, 2026, saying it would implement the Comprehensive Outbound Investment National Security Act and add biotechnology to the technologies covered by the program.

The proposal is not yet a final rule. Treasury opened it for public comment and said final implementing regulations will be issued later with an effective date. The distinction is important for companies and investors: the notice describes what the administration intends to regulate, but its requirements do not take effect merely because the proposal was published.

Under the framework described by Treasury, U.S. persons would have to notify the department about some transactions involving covered foreign companies working on specified technologies. Other transactions would be prohibited. The department said the rules would also apply to controlled foreign entities and would establish expectations for investors to conduct a reasonable and diligent inquiry before completing a deal.

Congress directed Treasury to write technical limits for semiconductors and microelectronics, artificial intelligence, quantum information technology, high-performance and supercomputing systems, and hypersonic systems. Treasury used separate authority in the law to add biotechnology, saying additional technologies may be covered when they could enable a country of concern’s military, intelligence, surveillance or cyber capabilities.

Associated Press and Bloomberg reports independently described the proposal as an expansion of U.S. controls on investment in Chinese high-technology and biotechnology companies. The reporting and Treasury’s own announcement agree on the central development: biotechnology would become a new front in the outbound-investment system, alongside sectors already treated as strategically sensitive.

Treasury Secretary Scott Bessent said the proposal was intended to prevent adversaries from using U.S. capital to develop technology that threatens national security while preserving an open investment environment. That is the administration’s stated rationale. The department has not said that every investment or commercial relationship in the named sectors would be barred; the eventual scope will depend on definitions, technical thresholds, covered parties and exceptions in the final regulation.

The proposal builds on an existing outbound-investment program rather than creating a conventional import tariff or export ban. Its focus is the flow of U.S. money and related support into foreign businesses developing specified technologies. Treasury said the rule would define covered transactions, identify exceptions, set notification requirements and explain potential penalties for violations.

President Donald Trump signed the fiscal 2026 defense authorization that included the COINS Act, and Treasury framed the new rule as implementation of that congressional mandate. The policy therefore combines legislation approved by Congress with choices left to the executive branch, including Treasury’s decision to bring biotechnology within the proposal.

The practical impact will become clearer after Treasury reviews comments and publishes final regulations. Key questions include which biotechnology activities meet the national-security threshold, how investors must assess foreign counterparties, which transactions qualify for exceptions and how broadly the government will enforce its due-diligence standard. Until those details are final, the October 22 action marks a policy proposal rather than an operative ban on all U.S. technology investment in China.

Sources and image credit

• U.S. Treasury — proposed rule announcement
• U.S. Treasury — Outbound Investment Security Program
• Associated Press — report on the proposed high-technology investment controls
• Bloomberg — report on proposed controls involving Chinese biotechnology firms
• Image: 颐园居 via Wikimedia Commons
• Image license: Creative Commons Attribution-ShareAlike 4.0